Cargando…

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis

INTRODUCTION: Etravirine has become an alternative in HIV/HCV coinfected patients because of safety and lack of interactions with anti-HCV drugs. The aim of this study was to establish the risk of liver toxicity in HIV/HCV coinfected patients receiving etravirine in the clinical setting, according t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luis Casado, Jose, Mena, Alvaro, Bañón, Sara, Moreno, Ana, Castro, Angeles, Perez-Elías, María J, Pedreira, JD, Moreno, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P042
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224832/ https://www.ncbi.nlm.nih.gov/pubmed/25394081 http://dx.doi.org/10.7448/IAS.17.4.19574

Ejemplares similares

Patient experience of remote musculoskeletal physiotherapy consultation during COVID-19: A mixed methods study
por: Perry, V., et al.
Publicado: (2022)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

ASPECTOS CLÍNICO‐EPIDEMIOLÓGICOS E DESFECHOS EM PACIENTES COM COVID‐19 EM GOIÂNIA
por: Borges, Moara A.S.B., et al.
Publicado: (2021)

Prévalence des anticorps dirigés contre l’annexine A2 chez des patients COVID-19 en réanimation
por: Salle, V., et al.
Publicado: (2021)

ANÁLISE DAS JUSTIFICATIVAS PARA A REALIZAÇÃO DOS TESTES RT-PCR PARA SARS-COV-2 EM BELO HORIZONTE E REGIÃO METROPOLITANA
por: Carvalho, Laura Fontoura Castro, et al.
Publicado: (2022)

MORTALIDADE MATERNA NO SUL DO MARANHÃO NA PANDEMIA DE COVID-19
por: Vitoi, Jose Vitor Barroso, et al.
Publicado: (2022)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy
por: Bañón, Sara, et al.
Publicado: (2014)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011
por: Lacombe, Jean-Marc, et al.
Publicado: (2014)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS)
por: Gomez-Ayerbe, Cristina, et al.
Publicado: (2014)

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study
por: Meijide, Héctor, et al.
Publicado: (2010)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
por: Ferrer, Elena, et al.
Publicado: (2014)

Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients
por: Brogueira, Pedro, et al.
Publicado: (2014)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Comparison of routine versus targeted HIV testing strategies: coverage and estimated missed infections in emergency room and primary care centre
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
por: Garcia-Broncano, Pilar, et al.
Publicado: (2018)

Who gets single tablet regimens (STR), and why?
por: Tarrier, Laura, et al.
Publicado: (2014)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users
por: Oprea, Cristiana, et al.
Publicado: (2014)

Evaluation of the degree of liver fibrosis and genetical characteristics in HIV patients with spontaneous clearance of HCV in Cartagena, Spain
por: Jesús Vera Méndez, Francisco, et al.
Publicado: (2014)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5pdhfcal2mei2ba5h36vksko7j